Cargando…

Fluvoxamine for the treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Marzolini, Catia, Marra, Fiona, Boyle, Alison, Khoo, Saye, Back, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846616/ https://www.ncbi.nlm.nih.gov/pubmed/35180411 http://dx.doi.org/10.1016/S2214-109X(21)00592-1

Ejemplares similares

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions
por: Back, David, et al.
Publicado: (2020)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
por: Marra, Fiona, et al.
Publicado: (2020)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
por: Seden, Kay, et al.
Publicado: (2017)

The challenge of HIV treatment in an era of polypharmacy
por: Back, David, et al.
Publicado: (2020)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
por: Mahdi, Mohamed, et al.
Publicado: (2022)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman
por: Feiterna-Sperling, Cornelia, et al.
Publicado: (2019)

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
por: Seftel, David, et al.
Publicado: (2021)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
por: Stader, Felix, et al.
Publicado: (2018)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Ritonavir and COVID-19: pragmatic guidance is important
por: Waters, Laura, et al.
Publicado: (2022)

Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model
por: Mills, Fergal P., et al.
Publicado: (2023)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing
por: Lewis, Joseph M., et al.
Publicado: (2016)

Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials
por: Guo, Christina M., et al.
Publicado: (2022)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021)

Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
por: Bramante, Carolyn T., et al.
Publicado: (2022)

Fluvoxamine pour les patients atteints de COVID-19 non hospitalisés
por: Wu, Peter E., et al.
Publicado: (2022)

Tolerability and safety of fluvoxamine and other antidepressants
por: Westenberg, HGM, et al.
Publicado: (2006)

Fluvoxamine alleviates paclitaxel-induced neurotoxicity
por: Tanimukai, Hitoshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_35mrt1mmgavv24vbldfde3rtos